We have tested Peroxisome proliferator-activated receptor γ co-activator 1α (PPARGC1α) which is a TF previously known to be involved in developing of NAFLD [37,38]. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.